Pubblicato studio pilota su ulcere sclerodermiche trattate con Luce Blu

14 July 2022

In Rheumatology and Therapy journal has been recently published the article “Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers”, presenting results of a pilot study carried out at the Scleroderma Unit of AOU Policlinico di Modena, Italy, directed by Dr Dilia Giuggioli.

The study aimed to assess the feasibility, the safety and the Blue Light efficacy in the treatment of systemic sclerosis (SSc) skin ulcers (SU). The authors report that SU represent one of the most frequent manifestations of systemic sclerosis (SSc), occurring in almost 50% of scleroderma patients. SSc-SU are painful, recurrent, hard to heal, and carry an increased risk of infection, osteomyelitis, and gangrene, sometimes requiring amputation. They are frequently responsible for pain and disability, which can severely affect SSc patients’ quality of life. The therapeutic strategy for SSc-SU includes both systemic and local pharmacological approaches, as well as local treatments based on wound bed preparation. However, despite the application of integrated treatments, SU sometimes continue to be hard-to-heal lesions. In this setting, searching for innovative therapies that support and promote SSc-SU healing is fundamental. In author’s experience, the application of blue light PBM produced faster healing of SU, with the formation of granulation tissue and regularization of margins. Blue Light patients also reported an improvement in pain in comparison with control subjects treated with standard systemic/local therapies alone.

According to the authors Blue Light Photobiomodulation is a promising tool to treat SSc-SU, in addition to conventional systemic and local therapies.

Ref. Spinella, A., de Pinto, M., Galluzzo, C. et al. Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers. Rheumatol Ther 9891–905 (2022). 

To read the articol: https://doi.org/10.1007/s40744-022-00438-9